History

2021

JUNE

International Liver Congress 2021 (EASL) Presentation of First in-class, Orally Active TLR Signaling Inhibitor Mosedipimod Attenuates Molecular, Biochemical and Histologic Features of NASH in vitro and in vivo

MAY

2021 NASH-TAG Conference Presentation of TLR Signaling Inhibition with Mosedipimod

2021 Keystone Symposia Poster Presentation of DAMP/Toll-like Receptor Signaling Attenuation with Mosedipimod: Effect in vitro and in two animal models of NASH

APRIL

AACR Poster Presentation of Suppressive Effect of PLAG on Tumor Progression and its Synergistic Therapeutic Effect with ICI therapy through Adenosine Clearance

CRIOM Phase 2 Stage 2 Patient Enrollment Completed 

MOU for Research Collaboration on Space Health Solution with Inha University

JANUARY

NASA Grant Funding Received to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space

2020

OCTOBER

Two RRS Presentations of EC-18’s Efficacy as ARS Treatment 

SEPTEMBER

ESMO Presentation of Synergistic PD-1 Antibody Anticancer Effect of EC-18 on Lung Cancer

AUGUST

COVID-19 Phase 2 IND US FDA Approval

JUNE

AACR Presentation of Synergistic PD-L1 Antibody Anticancer Effect of EC-18 on Bladder Cancer and EC-18’s Efficacy in CRIOM 

MAY

COVID-19 Phase 2 IND Korea MFDS Approval

1st Evaluation of the Space Radiation Treatment Development Project Passed by NASA

JANUARY

Biotech Showcase Company Presentation

2019

DECEMBER

AFRRI and DoD Collaboration for EC-18 as Radiation Medical Countermeasure

NOVEMBER

AASLD Presentation for EC-18 Efficacy in NASH

OCTOBER

AACR-NCI-EORTC Conference Presentation of EC-18 in Anti-Cancer and Anti-Metastasis Effect and CIN Phase 2 Part 1 Study Results

MAY

ARS Phase 2 Multi-Animal Studies FDA Approval

CIN Phase 2 Stage 1 Study Completed

FEBRUARY

CRIOM Phase 2 Stage 1 Patient Enrollment Study Completed

EU GMP Approved 

JANUARY

RNCP and CCRP’s support selected by NIH NIAID

2018

JUNE

Enzychem Lifesciences USA, Inc Established and Global Operation Launched 

MARCH

Fast Track Designation by US FDA on CRIOM

FEBRUARY

Listed on the KOSDAQ Stock Market (KOSDAQ: 183490)

2017

DECEMBER

Orphan Drug Designation by US FDA on ARS

JULY

CRIOM Phase 2 IND US FDA Approval

MAY

AAI Presentation

2016

DECEMBER

CIN Phase 2 IND Korea MFDS Approval

NOVEMBER

3rd KDDF Government Grant for Global New Drug Development Awarded

JULY

CIN Phase 2 IND US FDA Approval

MAY

AAI Annual Meeting Presentation

2015

OCTOBER

2nd KDDF Government Grant for Global New Drug Development Awarded

MAY

CIN Phase 1 IND Approved by US FDA 

MARCH

GMP Qualification Approved by Japan PMDA  

FEBRUARY

1st KDDF Government Grant for Global New Drug Development Awarded

JANUARY

Pharm Navi Selected by Korea MFDS 

New Technology Product Selected by the Korea MOTIE

2014

SEPTEMBER

CIN Investigators Initiated Study Completed at Asan Medical Center 

JULY

EC-18 Approved IND by Korea MFDS

2013

SEPTEMBER

Listed on the KONEX Stock Market

JANUARY

Plant 2 Certified for GMP by Korea MFDS

1st Human Clinical Trial for EC-18 Conducted by Myung-Ji Hospital of Kwandong University

2011

JUNE

New Health Technology Certification Acquired from KHIDI

MARCH

Columbus Project Company through the Korea MOHW

FEBRUARY

Successful Commercial Production of EC-18 

2009

APRIL

Plant Inspection Completed by Otto Brands GmbH, Hamburg, Germany for D – Cycloserine Production

2008

APRIL

Plant 1 Certified for GMP by Korea MFDS

2007

MARCH

INNOBIZ Certification Awarded by SMBA

2004

NOVEMBER

“Tower of Million-Dollar Export” Awarded by Korea MOTIE

2000

MARCH

Korea Good Technology Mark Acquired by Korea MEST

1999

JULY

Enzychem Lifesciences is Founded